12.01.2024 • NewsArkemaBatteriesinvestment

Arkema Acquires a Stake in Battery Start-up Tiamat

French chemical producer Arkema announced that it will become a shareholder of Tiamat, a start-up that designs, develops, industrializes and markets sodium-ion batteries, a new lithium-free technology. Tiamat was spun off from the Centre National de la Recherche Scientifique (CNRS) in 2017.

This investment will enable the Arkema to accelerate the development of technical solutions adapted to these batteries, which do not use lithium and can help to avoid the constraints associated with the supply of this metal.

Alongside strategic investors such as Stellantis Ventures and MBDA, Arkema contributed to Tiamat's recent €22 million fund-raising. With these funds as well as the support of the French government and the European Union, Tiamat wants to build a 5 GWh Giga-factory in France to produce sodium-ion battery cells. An initial tranche of 0.7 GWh could be operational by the end of 2025, and around 1,000 jobs could eventually be created, Arkema said.

"Our portfolio of advanced materials enables us to provide solutions for all our customers' battery technologies. The sodium-ion technology developed by Tiamat is very interesting, as it will enable to do away with the dependence to lithium and several strategic metals. This operation enriches our ecosystem and is perfectly in line with Arkema's strategy: innovative materials for a sustainable world" comments Armand Ajdari, Arkema's chief technology officer.

© Frank Peters/Getty Images
© Frank Peters/Getty Images

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.